Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

• R. C. Coombes,
• Sacha Howell,
• Simon R. Lord,
• Laura Kenny,
• Janine Mansi,
• Zahi Mitri,
• Carlo Palmieri,
• Linnea I. Chap,
• Paul Richards,
• William Gradishar,
• Sagar Sardesai,
• Jason Melear,
• Joyce O’Shaughnessy,
• Patrick Ward,
• Pavani Chalasani,
• Tobias Arkenau,
• Richard D. Baird,
• Rinath Jeselsohn,
• Simak Ali,
• Glen Clack,
• Ashwani Bahl,
• Stuart McIntosh,
• Matthew G. Krebs

Affiliations

R. C. Coombes

Imperial College, South Kensington

Sacha Howell

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre

Simon R. Lord

Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford

Laura Kenny

Imperial College, South Kensington

Janine Mansi

Guy’s and St Thomas’ NHS Foundation Trust

Zahi Mitri

OHSU Knight Cancer Institute

Carlo Palmieri

University of Liverpool

Linnea I. Chap

University of California

Paul Richards

Blue Ridge Cancer Center

William Gradishar

Northwestern University

Sagar Sardesai

US Oncology Research, OHC

Jason Melear

Baylor University Medical Center, Texas Oncology

Joyce O’Shaughnessy

Baylor University Medical Center, Texas Oncology

Patrick Ward

US Oncology Research, OHC

Pavani Chalasani

University of Arizona Cancer Center

Tobias Arkenau

Sarah Cannon Research Institute

Richard D. Baird

Cancer Research UK Cambridge Centre

Rinath Jeselsohn

Dana-Farber Cancer Institute

Simak Ali

Imperial College, South Kensington

Glen Clack

Carrick Therapeutics

Ashwani Bahl

Carrick Therapeutics

Stuart McIntosh

Carrick Therapeutics

Matthew G. Krebs

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre